MYC amplification is associated with reduced tumor immunogenicity as assessed by the recovery of IR recombination reads from prostate cancer genomics ...
The U.S. Food and Drug Administration (FDA) today released New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4)(1) , a sweeping guidance that codifies multiple regulatory ...
A new research paper was published in Volume 13 of Oncoscience on February 7, 2026, titled “Reduced immunogenicity of MYC amplified, metastatic prostate cancer.” ...
SK bioscience announced that, together with IDT Biologika (IDT) and Australian biotechnology company Vaxxas, it has been ...
cSchool of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China dDepartment of Biomedical Informatics, School of Basic Medical Sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results